The Claim
In patients with severe COVID-19 pneumonia, administration of high-dose intravenous vitamin C (6 g/day for 96 hours) was not associated with a statistically significant reduction in the need for invasive mechanical ventilation or vasopressor support, despite a numerical trend toward lower vasopressor use.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with severe COVID-19 pneumonia, receiving high-dose intravenous vitamin C for four days did not significantly reduce the need for breathing machines or blood pressure medications compared to those who did not receive it.
See the scientific wording
In patients with severe COVID-19 pneumonia, high-dose intravenous vitamin C (6 g/day for 96 hours) was not associated with a statistically significant reduction in the need for invasive mechanical ventilation (74% vs. 75%) or vasopressor support (34.2% vs. 55%), despite a numerical trend toward lower vasopressor use, indicating no clear clinical benefit for circulatory or respiratory support.
High doses of vitamin C lower inflammation in the lungs and help the body make more norepinephrine, a chemical that tightens blood vessels and raises blood pressure. Even though these changes happen, they are not strong enough to prevent patients from needing breathing machines or blood pressure drugs.
What the research says
1 studyIn very sick COVID patients, giving a lot of vitamin C through an IV didn’t reliably help them breathe better or need less medicine for blood pressure, even though some signs of inflammation improved.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.